DMXE
deoxymethoxetamine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
DMXE (deoxymethoxetamine) is an emerging synthetic dissociative of the arylcyclohexylamine class. It is a direct structural analog of MXE, distinguished by a milder and more sociable character. DMXE is an NMDA receptor antagonist, producing its effects by blocking glutamate-driven excitatory signaling in the brain.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, methoxetamine, phencyclidine +3 moreketamine, methoxetamine, phencyclidine, deschloroketamine, 2-FDCK, O-PCE show less
DMXE appeared on research chemical markets around October 2020, part of a recurring pattern of novel analogs emerging after the scheduling of predecessor compounds.[2] The structural modification from MXE was minimal — a single functional group swap on the phenyl ring — sufficient to sidestep compound-specific scheduling language. It circulates through online vendors and remains unscheduled at the U.S. federal level, though analog prosecution is possible.
Subjective effects include euphoria, dissociation, cognitive disconnection, geometric visual patterns, and sociability. The experience is warm and introspective — a muted, sociable dissociation frequently described as a gentler version of MXE, with stimulating qualities at lower doses giving way to deep immersive states at higher ones. Confusion, amnesia, compulsive redosing, and nausea are characteristic unsought effects.
No physical dependence syndrome has been documented, but psychological dependence with compulsive within-session redosing is reported, and no toxicity data exist in any species. Class-level hazards — seizures and cardiovascular disturbance,[3] substance-induced psychosis,[4] and progressive bladder damage with chronic use[5] — have not been assessed for DMXE specifically, and the margin between a strong and dangerous dose is unknown. Three peer-reviewed papers address the compound directly;[1][6][7] no clinical trials or controlled human safety data have been published.
History[edit]
History
Discovery
DMXE does not appear in scientific literature prior to 2020. The compound emerged on online research chemical markets in approximately October 2020, positioned as a replacement for methoxetamine (MXE) following MXE's progressive scheduling across multiple jurisdictions.[2] The structural modification was minimal — replacing MXE's 3-methoxy group with a methyl group — preserving dissociative activity while producing a compound not named in existing scheduling language. No published account identifies who first synthesized DMXE or where it originated.
Forensic detection
Forensic laboratories in Slovenia first detected DMXE in December 2020, followed by confirmed identification in Denmark in February 2021.[8][9] Tanaka et al. published the first peer-reviewed forensic characterization in 2022, identifying DMXE in seized products in Japan.[6] In the United States, the CFSRE first identified the compound in July 2025 from drug material samples in the New England region; only two samples had been catalogued as of October 2025.[9]
Scientific characterization
The first pharmacological data appeared in 2022, measuring DMXE's NMDA potency in mouse neuronal preparations and confirming binding at the same channel site as ketamine and PCP.[1] The only other primary research — published in 2025 — achieved the first separation of DMXE's two mirror-image enantiomers using chirality analytical methods.[7] No further pharmacological, toxicological, or clinical studies have been published as of May 2026.
Chemistry[edit]
Chemistry
Structural class
DMXE belongs to the arylcyclohexylamine chemical class — a family defined by a cyclohexane ring bonded to both an aromatic group and an amine nitrogen. This scaffold is shared by ketamine, PCP, and MXE, all NMDA receptor antagonists.
DMXE is a direct structural analog of MXE, differing only at the 3-position on the phenyl ring: a methyl group (–CH₃) replaces MXE's methoxy group (–OCH₃). This substitution removes a hydrogen-bond acceptor and increases the compound's fat solubility.[2]
Molecular properties
| Molecular formula | C₁₅H₂₁NO |
| Molecular weight | 231.33 g/mol |
The systematic name is 2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one. DMXE is structurally related to deschloroketamine (which lacks any 3-phenyl substituent) and to N-ethylnorketamine (sharing the N-ethyl group).
Stereochemistry
DMXE has one chirality center at C2 of the cyclohexanone ring, producing two enantiomers (R and S). The compound is sold and consumed as a racemic mixture. Seibert et al. achieved the first enantioseparation using capillary electrophoresis and HPLC with chiral columns.[7]
The relative potency of individual enantiomers has not been characterized — unlike ketamine, where the S-enantiomer is roughly four times more potent than R-ketamine at the NMDA. Enantiomeric variation may contribute to the batch-to-batch variability in effects reported by users.
Physical properties
DMXE hydrochloride presents as a white to off-white crystalline powder. The free base is sparingly soluble in water and soluble in common organic solvents.citation needed Recommended storage is at −20 °C, protected from light and moisture. No published degradation studies exist.
Pharmacology[edit]
Pharmacology
Mechanism of action
DMXE blocks the NMDA glutamate receptor — the brain's primary excitatory signaling channel — by binding to the phencyclidine (PCP) site inside the ion channel pore. This blockade is use-dependent: the channel must open before the drug can enter and occlude it. The same mechanism underlies the dissociative effects of ketamine, PCP, and MXE.[1]
In the only published potency measurement, DMXE showed NMDA-blocking strength comparable to MXE in mouse neuronal preparations.[1] Computational docking confirmed that DMXE occupies the same binding pocket within the NMDA channel as other arylcyclohexylamines.[1]
No broad receptor screening has been published. By structural analogy with MXE — which showed affinity for the SERT and sigma receptors[10] — DMXE may interact with targets beyond NMDA. The methyl-for-methoxy substitution could alter these secondary affinities, but this remains structural inference, not established pharmacology.
Pharmacokinetics
No human pharmacokinetic data have been published for DMXE. Bioavailability, time to peak blood levels, half-life, and protein binding are all unknown.
Metabolic pathway predictions are derived from MXE data, which identified liver enzymes responsible for removing the ethyl group from the nitrogen as the primary breakdown pathway.[11] The main predicted metabolite is nor-DMXE (the de-ethylated form). Secondary pathways likely include ring hydroxylation followed by conjugation for excretion.[11]
One metabolic pathway important for MXE — removal of the methoxy group — is unavailable for DMXE, which lacks that group. How this affects overall clearance and metabolite activity is unknown. safety citation needed
Neuroscience[edit]
Neuroscience
Where it acts
No neuroimaging or electrophysiology studies have been conducted with DMXE. Based on the NMDA antagonist class — principally ketamine research — DMXE is expected to disrupt communication between the cortex and thalamus, the relay station that normally integrates sensory information into a coherent experience.[12] This cortical-subcortical disconnection produces the characteristic dissociative state: progressive detachment from body, environment, and self.
At the cellular level, blocking NMDA receptors on inhibitory interneurons paradoxically increases excitatory activity in pyramidal neurons — the glutamate surge that may underlie the stimulating quality users report at lower DMXE doses.
Why it matters
NMDA antagonists including ketamine have been classified as psychoplastogens — compounds that promote structural rewiring of neural connections, including growth of new dendritic branches and synapses.[12] This property underlies ketamine's rapid antidepressant effects, and MXE analogs have also shown antidepressant-like activity in animal models.[13]
Whether DMXE engages these neuroplasticity pathways at typical doses is unknown, but the possibility means acute use could produce lasting circuit-level changes beyond the intoxication period.
Does DMXE promote structural brain rewiring comparable to ketamine? The methyl substitution's downstream effects on plasticity signaling are uncharacterized. What does each enantiomer contribute — given that ketamine's mirror-image forms differ four-fold in potency, DMXE's enantiomeric profile could matter significantly.[7]
Subjective Effects[edit]
Subjective Effects
DMXE produces a dissociative experience defined by unusual warmth and sociability at lower doses — a quality that separates it from the clinical detachment of ketamine. As dose increases, the social and stimulating character gives way to deeper cognitive disconnection, introspective immersion, and geometric visual distortions. Set, setting, and prior dissociative experience substantially shape the quality of effects, and individual response variability is high — partly due to the compound's racemic mixture nature and variable vendor purity.
Within its class, DMXE is most frequently compared to MXE, which it was designed to replace, and is generally described as milder at equivalent dissociative depth. Relative to ketamine, it offers greater subjective warmth, more introspective character, and a longer experience.
Effect Grid
Clear dissociative effects emerge. Motor control impairment becomes noticeable — walking is unsteady and fine motor tasks become difficult. Bodily dissociation deepens: numbness spreads, and the boundary between body and environment begins to blur. Euphoria intensifies with a warm, rounded quality frequently compared to MXE.
Introspection enhancement is a defining feature at this tier. Thought patterns turn inward, and contemplative states arise naturally. Mild geometric visual distortions appear with eyes closed — patterning in cool-toned palettes. Music enhancement is prominent, and time alteration becomes apparent. Auditory distortion may add a reverberant quality to sounds.
This is the tier where compulsive redosing urge is most consequential — the desire to extend or deepen the experience during the offset phase is commonly reported. Pre-portioning doses and removing access to remaining material is strongly recommended.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch suppression · Vestibular distortion · Ganzfeld effect · Sensory deprivation · Sleep-transition hallucinations · Auditory distortion · Music enhancement · Visual acuity suppression · Visual haze / noise · Touch enhancement · Brightness alteration · Color alteration · Auditory suppression · Holotropic state · Peripheral vision distortion · Tracers · Visual drifting · Visual morphing · Color suppression · Dreaming suppression · Color enhancement · Tinnitus · After-images · Auditory misinterpretation · Dreaming enhancement · Geometry · Sound sensitivity · Visual diffraction · Taste suppression · Visual magnification · Environmental patterning · Peripheral misidentification · Synesthesia · Visual breathing · Visual melting · Internal hallucinations · Visual processing suppression · External hallucinations · Object transformations · Perspective hallucinations · Environmental orbism / cubism · Visual flipping · Auditory hallucinations · Object activation · Visual recursion · Shadow people
Sleep-transition hallucinations · Auditory distortion · Music enhancement · Visual acuity suppression · Visual haze / noise · Touch enhancement · Brightness alteration · Color alteration · Auditory suppression · Holotropic state · Peripheral vision distortion · Tracers · Visual drifting · Visual morphing · Color suppression · Dreaming suppression · Color enhancement · Tinnitus · After-images · Auditory misinterpretation · Dreaming enhancement · Geometry · Sound sensitivity · Visual diffraction · Taste suppression · Visual magnification · Environmental patterning · Peripheral misidentification · Synesthesia · Visual breathing · Visual melting · Internal hallucinations · Visual processing suppression · External hallucinations · Object transformations · Perspective hallucinations · Environmental orbism / cubism · Visual flipping · Auditory hallucinations · Object activation · Visual recursion · Shadow people
Body schema distortion · Dizziness · Nystagmus (eye wobbles) · Body high · Muscle relaxation · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Bodily heaviness · Headache · Heart rate perception changes · Laughter fits · Nausea · Physical fatigue · Pupil dilation · Stimulation · Vasoconstriction · Wakefulness · Bodily lightness · Dry mouth · Insomnia · Nasal congestion · Tactile euphoria · Increased urination · Trembling · Vomiting · Bodily pressures · Brain zaps · Breathing alteration · Excessive sweating · Involuntary body movements · Muscle tension · Restlessness · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Body high · Muscle relaxation · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Bodily heaviness · Headache · Heart rate perception changes · Laughter fits · Nausea · Physical fatigue · Pupil dilation · Stimulation · Wakefulness · Bodily lightness · Dry mouth · Insomnia · Nasal congestion · Tactile euphoria · Increased urination · Trembling · Vomiting · Bodily pressures · Brain zaps · Breathing alteration · Excessive sweating · Involuntary body movements · Muscle tension · Restlessness · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Information processing suppression · Memory fragmentation · Memory suppression · Thought disorganization · Analysis suppression · Cognitive euphoria · Cognitive fatigue · Immersion enhancement · Introspection enhancement · Aesthetic enhancement · Language suppression · Motivation suppression · Novelty enhancement · Suggestibility enhancement · Thought deceleration · Creativity enhancement · Humor enhancement · Cognitive flexibility · Conceptual thinking · Delusions of sobriety · Multiple thought streams · Openness enhancement · Pattern recognition suppression · Thought connectivity · Thought loops · Focus enhancement · Motivation enhancement · Aesthetic suppression · Creativity suppression · Memory replays · Cognitive dysphoria · Pattern recognition enhancement · Information processing enhancement · Analysis enhancement · Amnesia · Delirium · Delusions
Thought disorganization · Analysis suppression · Cognitive euphoria · Cognitive fatigue · Immersion enhancement · Introspection enhancement · Aesthetic enhancement · Language suppression · Motivation suppression · Novelty enhancement · Thought deceleration · Creativity enhancement · Humor enhancement · Cognitive flexibility · Conceptual thinking · Delusions of sobriety · Multiple thought streams · Openness enhancement · Pattern recognition suppression · Thought connectivity · Thought loops · Focus enhancement · Motivation enhancement · Aesthetic suppression · Creativity suppression · Memory replays · Cognitive dysphoria · Pattern recognition enhancement · Information processing enhancement · Analysis enhancement · Amnesia · Delirium · Delusions
Emotional suppression · Simultaneous emotions · Anxiety · Catharsis · Emotional lability · Empathy enhancement · Empathy suppression · Anhedonia · Dysphoria · Irritability
Emotional lability · Empathy enhancement · Empathy suppression · Anhedonia · Dysphoria · Irritability
Social connection · Disinhibition · Sociability suppression · Compulsive behavior reduction · Trust enhancement · Automaticity · Craving · Emotional susceptibility · Sociability enhancement · Communication enhancement · Flow state · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Trust enhancement · Automaticity · Craving · Emotional susceptibility · Sociability enhancement · Communication enhancement · Flow state · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Time cessation
Transpersonal feelings · Voidness · Death-rebirth sequence · Entity contact · Near-death experience · Transpersonal visions
Near-death experience · Transpersonal visions
Mindfulness enhancement · Recursive awareness
Timeline
Slower emergence than insufflated route — a gentle shift in awareness and mild bodily warmth over 15–30 minutes.
Extended build with a more sedating quality than the insufflated route. Dissociation and euphoria develop gradually.
Longer, more rounded peak than insufflated. Deeper sedation component; introspective and dissociative effects are sustained but less sharp in onset.
Prolonged resolution with lingering sedation. Environmental awareness returns gradually. Redosing urge may emerge but is less acute than with insufflation.
Residual cognitive softness and mood lift, similar to insufflated route but potentially more prolonged due to slower elimination.
⚠ Do not drive or operate heavy machinery for at least 8 hours after last dose.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- Negligible
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · methoxetamine · phencyclidine
Safety
DMXE has no published toxicological profile. No lethal dose, no therapeutic index, and no controlled human safety data exist. All safety information below is derived from class-level evidence (ketamine, MXE, PCP analogs), structural inference, and community reports. The margin between a strong and dangerous dose is unknown.Toxicity
Acute toxicity
No cases of acute DMXE toxicity have been reported in peer-reviewed literature. The CFSRE had recorded zero toxicology cases involving DMXE as of October 2025.[9] No lethal dose data have been published in any species. safety citation needed
Class-level acute risks for arylcyclohexylamines include:
- Seizures: Documented in acute MXE intoxication, alongside slowed heart rate and abnormal heart rhythm[3]
- Cardiovascular disturbance: Rapid heart rate, elevated blood pressure, and abnormal heart rhythms are reported across the class[3]
- Muscle breakdown: The first confirmed case of 3-methyl-PCP use — a compound sharing DMXE's 3-methylphenyl ring — produced muscle breakdown and acute kidney injury.[14] This structural parallel warrants caution but is not direct evidence for DMXE. inferred
- Fatal outcome: A death involving O-PCE (a compound sharing DMXE's ethylamino group and core structure) occurred in combination with venlafaxine.[15] No fatalities attributed to DMXE alone or in combination have been reported.
Chronic toxicity
Bladder damage: Chronic heavy ketamine use causes progressive lower urinary tract damage — inflammation, scarring, reduced bladder capacity, and in severe cases kidney failure.[5][16] Whether DMXE carries the same risk is unknown; this is a class-level concern for all arylcyclohexylamine dissociatives used repeatedly. inferred
Brain damage: A single intravenous MXE dose produced psychotic symptoms with measurable metabolic changes in the prefrontal cortex on brain imaging.[4] Similar persistent psychosis and brain changes have been documented following 3-MeO-PCP use.[17] Repeated NMDA blocker use is associated with neuronal damage in animal models, though relevance to human use remains debated.[18]
Psychological Risks
NMDA receptor blockers as a class can produce paranoia, delusions, thought disorganization, and loss of reality testing at high doses. Community reports describe confusion and delirium at heavy DMXE doses (60+ mg insufflated).[19][20]
Substance-induced psychotic episodes have been documented for MXE[4] and 3-MeO-PCP,[17] with cases persisting beyond the acute intoxication period. Individuals with personal or family history of psychotic disorders are at elevated risk.
Amnesia and memory fragmentation occur at moderate-to-heavy doses, with complete blackout possible at heavy doses.[19] Combined with impaired motor control and impaired judgment, this creates significant risk of accidental injury during intoxication.
Tolerance & Dependence
No controlled studies on DMXE tolerance or dependence exist.
Tolerance develops rapidly with repeated use, consistent with NMDA antagonist pharmacology.[19][20] Cross-tolerance is expected with other NMDA antagonists (ketamine, MXE, PCP, deschloroketamine, 2-FDCK), though no published data confirm this for DMXE specifically.
Physical dependence has not been characterized. The NMDA antagonist class does not typically produce physical withdrawal syndromes comparable to opioids or benzodiazepines, though low mood, mental fog, and cravings may follow cessation of heavy use.
Psychological dependence is the more prominent concern. Users describe a strong compulsive redosing urge during the comedown — next-day craving is low, but within-session redosing drive is notable.[19] At least one report has been categorized under addiction and habituation.[20]
No formal abuse liability assessments have been conducted. safety citation needed
Drug Interactions
No published drug interaction studies exist for DMXE. All interaction data represent class-level inference. inferred
Serotonin-active drugs (SSRIs, SNRIs, tramadol, monoamine oxidase inhibitors): If DMXE shares MXE's SERT affinity,[10] combining it with serotonergic drugs risks serotonin syndrome. A fatal case involving O-PCE combined with the SNRI venlafaxine underscores this concern.[15] MAO inhibitors may substantially intensify effects; community reports strongly advise against this combination.[19]
Depressants (opioids, alcohol, benzodiazepines): Additive sedation and respiratory depression. The dissociative state impairs protective reflexes (cough, gag), increasing aspiration risk when combined with depressants.
Stimulants (amphetamines, cocaine): Cardiovascular strain from combined stimulant and NMDA-blocker effects on heart rate and blood pressure.
Other NMDA antagonists: Additive dissociative effects and potential for dangerously deep sedation.
Contraindications
No substance-specific contraindication data exist. The following are derived from class-level evidence and pharmacological mechanism. inferred
Absolute contraindications:
- Psychotic disorders (personal or family history): NMDA antagonists are psychosis-inducing agents; persistent psychosis has been documented in the arylcyclohexylamine class[4][17]
- Concurrent MAO inhibitor use: Dangerously intensified serotonergic and stimulant effects safety citation needed
- Concurrent high-dose SNRI/SSRI use: Serotonin syndrome risk if DMXE possesses serotonin transporter activity; the O-PCE + venlafaxine fatality is the most relevant case[15]
Relative contraindications:
- Heart conditions: Rapid heart rate and elevated blood pressure are class-level effects[3]
- Kidney impairment: Reduced clearance of compound and metabolites; muscle breakdown risk by structural parallel[14]
- Liver impairment: Impaired breakdown may alter drug levels unpredictably[11]
- Seizure history: Seizures documented in MXE intoxication[3]
- Pregnancy: NMDA receptor blockade may disrupt brain development; no reproductive safety data exist safety citation needed
- Bladder or urinary tract disease: Class-level risk of progressive urinary tract damage with repeated use[5]
Harm Reduction[edit]
Forms & Identification
DMXE arrives as an unregulated white to off-white powder with no manufacturer quality controls. Because multiple dissociative powders are visually identical, reagent testing is essential — not to confirm DMXE specifically (no reagent reliably distinguishes it from all related compounds) but to rule out dangerous substitutions such as synthetic opioids or stimulants.
Fentanyl test strips should be used on every batch. Powder from different vendors or different batches from the same vendor may vary substantially in purity and potency, making dose consistency unreliable even with a milligram scale.
Guidelines
- Test every batch with reagent kits and fentanyl test strips before use
- Weigh doses on a milligram-scale balance — do not estimate powder by eye
- Start with a low dose and wait at least 90 minutes before considering redosing, especially oral
- Have a sober companion present, particularly at moderate or higher doses
- Keep water accessible but avoid consuming large quantities — stay hydrated without overdrinking
- Clear the environment of sharp objects, open flames, and fall hazards before onset
- Do not drive or operate machinery for at least 8 hours after use
- Predetermine your total dose for the session and set the remaining material aside — the compulsive redosing urge is widely reported and can escalate dose beyond intended levels
Set & Setting
Dissociative experiences are strongly shaped by mindset and environment. Use in a calm, familiar setting with a sober companion present — particularly at higher doses where motor control and judgment are impaired. Avoid unfamiliar or physically hazardous environments (heights, water, traffic).
Prior dissociative experience substantially modulates the character of DMXE's effects. First-time users should start well below their target dose and allow the full duration to pass before considering the experience representative.
Aftercare & integration. The hours following a dissociative experience may include residual mental fog, emotional flatness, or a sense of unreality. These aftereffects typically resolve within 24–48 hours. Rest, light food, and quiet activity support recovery.
If the experience was psychologically intense — particularly at higher doses — allow time to process before returning to demanding tasks. Journaling or conversation with a trusted person can help integrate unusual perceptual or cognitive experiences. Persistent feelings of unreality, depersonalization, or cognitive difficulty beyond 72 hours warrant professional consultation.
Recovery & Support
DMXE's compulsive redosing pattern can develop into habitual use, particularly when the compound is used to manage emotional distress. If use has become frequent or difficult to control, support is available.
SAMHSA National Helpline: 1-800-662-4357 (US, free, confidential, 24/7). Online resources include harm reduction communities that provide peer support for dissociative use concerns. Professional substance use counseling — particularly approaches effective for dissociative and ketamine use patterns — can help establish healthier patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable dissociation is not inherently dangerous, but the following signs require immediate help: seizure activity, loss of consciousness with inability to rouse, vomiting while unconscious or deeply dissociated, chest pain, blue or grey lips, or signs of extreme agitation with self-harm risk.
Immediate steps:
- 1. Call emergency services immediately if the person is unresponsive, seizing, or has stopped breathing
- 2. Place an unresponsive breathing person in the recovery position (on their side) to prevent choking on vomit
- 3. Do not attempt to restrain someone who is agitated unless they are in immediate danger of harming themselves
- 4. Do not induce vomiting
- 5. Stay with the person and monitor breathing until help arrives
What to tell the dispatcher: Name the substance (DMXE, a dissociative), the approximate amount taken, the time of ingestion, the route, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for NMDA antagonist intoxication. Treatment is supportive.
Legal Status[edit]
Legal Status
DMXE occupies a legal gray zone in most jurisdictions. As a novel psychoactive substance that appeared in late 2020, it has been specifically controlled in some countries under broad arylcyclohexylamine or blanket NPS legislation, while remaining unscheduled in others. The compound is monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Early Warning System since detections in Slovenia (December 2020) and Denmark (February 2021).[8][9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | DMXE is not listed in DEA schedules. MXE (parent compound) placed in Schedule I effective July 6, 2022.[21] Federal Analogue Act (21 U.S.C. § 813) may apply given structural and pharmacological similarity to Schedule I MXE. |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under broad arylcyclohexylamine provisions. Penalties: up to 5 years imprisonment for possession, 14 years for supply.citation needed |
| Germany | Controlled (NpSG) | Restricted under the Neue-psychoaktive-Stoffe-Gesetz. Limited to industrial and scientific use.citation needed |
| Japan | Designated substance (likely) | DMXE identified in seized illegal products;[6] specific designation status under pharmaceutical law not confirmed via official government source. |
| European Union | EMCDDA EWS monitored | Tracked via Early Warning System since 2020–2021. Individual member states may impose additional controls.[8] |
| Canada | Possibly Schedule I (CDSA) | Secondary source claim; editorial verification against Controlled Drugs and Substances Act schedules required.citation needed |
| Australia | Controlled (requires license) | Secondary source claim; verification against SUSMP/TGA schedules required.citation needed |
Analog Act considerations
In the United States, the Federal Analogue Act treats substances "substantially similar" in structure or pharmacological effect to a Schedule I or II substance as Schedule I if intended for human consumption. DMXE satisfies both tests: it differs from Schedule I MXE by a single functional group, and its NMDA-blocking potency is comparable.[1][21] Prosecution under the Act has been applied to other arylcyclohexylamine analogs.[22]
references
- [1]
- [2] ^abcWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [3]
- [4] ^abcdMoccia L, Tofani A, Mazza M, Covino M, Martinotti G, Schifano F, Janiri L, Di Nicola M (2019) Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study — Journal of Psychoactive Drugs doi:10.1080/02791072.2019.1578444
- [5] ^abcCastellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M (2020) What urologists need to know about ketamine-induced uropathy: A systematic review — Neurourology and Urodynamics doi:10.1002/nau.24341
- [6] ^abcTanaka R, Kawamura M, Mizutani S, Hakamatsuka T, Kikura-Hanajiri R (2022) Identification of Three Arylcyclohexylamines (MXPr, MXiPr, and DMXE) in Illegal Products — Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan) doi:10.1248/yakushi.21-00235